I was lucky enough to sneak out of work to hear the conference...

I was lucky enough to sneak out of work to hear the conference call. Mario sounded professional and like he can really bring this product to market with the experience he has in other product launches in big pharma companies he has worked for

He also said that if he launched a product like this with no competition and achieved 5% market share, the product would have been seen as a failure at a big company...

Well for RSH a market penetration of only %5 would be revenue to RSH if $260 000 000 (on slide 33 of yesterday’s announcement) and this is only for North America, Germany, UK and Australia...

Gee at such a cheap valuation shouldn’t this stock re rate a hell of a lot!??

What about the Asian market - respiratory diseases are rife there and so is air pollution..?

I liked the questions at the end of the conference call about commercialisation and partnerships etc and I believe Mario had a balanced and realistic approach.

Good luck to him and he team and I’m very sure that mums like me will buy this when it’s available. I also think that when potential purchasers of the product, be they asthma sufferers or their carers, Get to see one working I believe they will be impressed and appreciate the piece of mind this provides them.

As Mario said on the call, the other chronic diseases like heart conditions and diabetes have monitoring devices but Asthmatics don’t!!

This is truely disruptive and it’s all unfolding so quickly. I actually very excited to have found this stock!

Thx fellow RSH posters and good luck to us all!